XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Debt - (Tables)
6 Months Ended
Jun. 30, 2024
Debt Instrument, Redemption [Line Items]  
Summary of liability for sale of future royalties

    

Six Months Ended June 30, 

Liability for sale of future royalties- (current and noncurrent)

2024

Beginning balance as of December 31, 2023

$

1,814,097

Less: Non-cash royalty revenue payable to Royalty Pharma

(73,349)

Plus: Non-cash interest expense recognized

102,340

Plus: Cash received from Royalty Pharma

241,792

Ending balance

$

2,084,880

Effective interest rate as of June 30, 2024

 

9.9%

1.50% Convertible senior notes due 2026  
Debt Instrument, Redemption [Line Items]  
Summary of convertible notes

    

June 30, 2024

December 31, 2023

Principal

$

287,500

$

287,500

Less: Debt issuance costs

 

(2,694)

 

(3,287)

Net carrying amount

$

284,806

$

284,213

Summary of interest expense recognized related to the Convertible Notes

Three Months Ended June 30, 

Six Months Ended June 30, 

    

2024

2023

    

2024

2023

Contractual interest expense

$

1,066

$

1,066

$

2,142

$

2,135

Amortization of debt issuance costs

 

295

290

591

578

Total

$

1,361

$

1,356

$

2,733

$

2,713

Effective interest rate

 

1.9

%

1.9

%

1.9

%

1.9

%

Blackstone Credit Agreement  
Debt Instrument, Redemption [Line Items]  
Schedule of credit agreement

    

June 30, 2024

December 31, 2023

Principal

$

$

300,000

Less: Debt issuance costs

 

Repayment of senior secured term loan

(300,000)

Net carrying amount

$

$

Summary of interest expense recognized related to debt

Three Months Ended

Six Months Ended

June 30, 

June 30, 

2024

2023

2024

2023

Contractual interest expense

$

$

9,354

$

$

18,532

Amortization of debt issuance costs

 

 

272

423

Total

$

$

9,626

$

$

18,955

Effective interest rate

%

13.4

%

%

13.4

%